Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Nov;19(11):921-928.
doi: 10.1080/14737140.2019.1685879. Epub 2019 Nov 4.

Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma

Evangelos Eleutherakis-Papaiakovou  1 , Maria Gavriatopoulou  1 , Ioannis Ntanasis-Stathopoulos  1 , Efstathios Kastritis  1 , Evangelos Terpos  1 , Meletios A Dimopoulos  1
Affiliations
Review

Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma

Evangelos Eleutherakis-Papaiakovou et al. Expert Rev Anticancer Ther. 2019 Nov.

Abstract

Introduction: Despite major advances in the therapeutic management of multiple myeloma (MM), it remains an incurable disease. Several combinations of monoclonal antibodies with novel agents are being investigated with promising results in order to prolong progression-free and overall survival.Areas covered: This paper aims to critically present available data from clinical trials investigating the combination of elotuzumab with pomalidomide and dexamethasone in refractory/relapsed MM patients and determine its current role in clinical practice.Expert opinion: Pomalidomide-based combinations with monoclonal antibodies have been shown to be effective in patients with MM who are refractory to or have relapsed following treatment with lenalidomide and/or a proteasome inhibitor (PI). These regimens seem to be more effective than the standard combination of pomalidomide with dexamethasone alone. Taking into consideration that the vast majority of MM patients will receive upfront treatment including a PI and lenalidomide in the near future, pomalidomide-based triplets, such as elotuzumab-pomalidomide-dexamethasone, will become the standard of care in the second line of therapy.

Keywords: Elotuzumab; immunomodulatory drugs; monoclonal antibody; multiple myeloma; pomalidomide; treatment.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

MeSH terms

LinkOut - more resources